PAVM (PAVmed) Cyclically Adjusted PB Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAVM PAVmed Inc PAVM
32 GF Score
Price $4.92
GF Value $1.21
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is PAVmed Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PAVmed  (NAS:PAVM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PAVmed Cyclically Adjusted PB Ratio Related Terms


PAVmed Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for PAVmed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PAVmed Cyclically Adjusted PB Ratio Chart

PAVmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PAVmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PAVM vs BDMD, NSPR, TELA: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, PAVmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PAVmed's Cyclically Adjusted PB Ratio falls into.


PAVM
32GF Score
PAVmed Inc PAVM
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PAVmed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PAVmed's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, PAVmed's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.29/333.9520*333.9520
=4.290

Current CPI (Jun. 2026) = 333.9520.

PAVmed Quarterly Data

Book Value per Share CPI Adj_Book
201609 38.133 241.428 52.747
201612 -10.633 241.432 -14.708
201703 -143.800 243.801 -196.973
201706 -168.333 244.955 -229.492
201709 -203.433 246.819 -275.250
201712 -121.281 246.524 -164.292
201803 -37.410 249.554 -50.062
201806 82.831 251.989 109.773
201809 28.593 252.439 37.826
201812 -72.450 251.233 -96.304
201903 -125.650 254.202 -165.070
201906 -48.658 256.143 -63.439
201909 -50.790 256.759 -66.060
201912 -68.000 256.974 -88.370
202003 -176.724 258.115 -228.647
202006 -129.368 257.797 -167.584
202009 -139.645 260.280 -179.171
202012 -4.514 260.474 -5.787
202103 263.530 264.877 332.254
202106 219.848 271.696 270.224
202109 172.968 274.310 210.576
202112 308.578 278.802 369.618
202203 225.104 287.504 261.471
202206 100.642 296.311 113.427
202209 30.849 296.808 34.710
202212 -58.933 296.797 -66.311
202303 -110.821 301.836 -122.613
202306 -142.544 305.109 -156.019
202309 -173.590 307.789 -188.346
202312 -198.685 306.746 -216.307
202403 -243.563 312.332 -260.423
202406 -242.440 314.175 -257.701
202409 -22.820 315.301 -24.170
202412 -15.579 315.605 -16.485
202503 33.481 319.799 34.963
202506 19.314 322.561 19.996
202509 11.007 324.800 11.317
202512 10.010 324.054 10.316
202603 5.705 330.213 5.770
202606 4.290 333.952 4.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is PAVmed (PAVM) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of $4.92 is trading 306.6% above its estimated GF Value™ of $1.21. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for PAVM:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $1.21 vs. price of $4.92 (306.6% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the PAVM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PAVmed Business Description

Other Exchanges 1P5:Germany
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
32GF Score

Get the complete analysis for PAVM

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.92
Price
$1.21
GF Value